

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VIVA BIOTECH HOLDINGS

维亚生物科技控股集团

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON NOVEMBER 9, 2020

The Board announces that the resolution as set out in the Notice was duly passed by the Shareholders as an ordinary resolution by way of poll at the Extraordinary General Meeting.

The board of directors (the “**Board**”) of VIVA BIOTECH HOLDINGS (the “**Company**”) is pleased to announce the poll results of the second extraordinary general meeting of the Company (the “**Extraordinary General Meeting**”) held at 2/F Meeting Room, 334 Aidisheng Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, PRC on Monday, November 9, 2020 at 10:00 a.m.

Reference is made to the Company’s circular (the “**Circular**”) in connection with the Extraordinary General Meeting and notice of the Extraordinary General Meeting (the “**Notice**”) dated October 16, 2020. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting result in respect of the resolution proposed at the Extraordinary General Meeting was as follows:

Ordinary Resolution		Number of Votes (%)	
		For	Against
1.	(a) The Share Purchase Agreement and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified; and	945,908,689 (99.99%)	3,000 (0.01%)
	(b) Any one Director be and is hereby authorized to sign, execute and deliver or authorize the signing, execution and delivery of all such documents (including affixing the common seal of the Company thereon) and to do all such things as he or she may in his or her absolute discretion consider necessary, expedient or desirable to implement and/or to give effect to or otherwise in connection with the Share Purchase Agreement and the transactions contemplated thereunder.	945,908,689 (100%)	0 (0.00%)

As more than 50% of the votes were cast in favour of the above resolution, the resolution was passed as an ordinary resolution at the Extraordinary General Meeting.

The total number of issued Shares as at the date of the Extraordinary General Meeting was 1,912,469,790 Shares, which was the total number of Shares entitling the Shareholders to attend and vote on the resolution. There were no Shares entitling the holders to attend and abstain from voting in favour at the Extraordinary General Meeting as set out in rule 13.40 of the Listing Rules. There were no restrictions on any Shareholders casting votes on the proposed resolution at the Extraordinary General Meeting. No person was required under the Listing Rules to abstain from voting on the resolution proposed at the Extraordinary General Meeting and no party has stated its intention in the Circular to vote against or to abstain from voting the resolution proposed at the Extraordinary General Meeting.

Tricor Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, was appointed as the scrutineer for the vote-taking at the Extraordinary General Meeting.

By order of the Board
VIVA BIOTECH HOLDINGS
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, November 9, 2020

As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao, and Mr. Ren Delin; a Non-executive Director, namely, Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.